MediGence: Enabling Better Health Decisions

Most children diagnosed with cancer around the globe have a form of paediatric leukaemia. Due to advances in chemotherapy, radiation therapy and bone marrow or stem cell transplantation, the majority of children diagnosed today with pediatric leukaemia have a much improved chance of survival; however, a significant number of children have either relapsed from treatment or have become resistant to the treatments.

In the past few years, there have been revolutionary advances in CAR-T Therapy for pediatric cancers such as leukaemia, which has the potential to dramatically change how pediatric leukaemia can be treated and provide some level of hope for these children and their families.

What is Pediatric Leukaemia?

Basically, leukaemias are cancers of blood cells and bone marrow that result from the continuous and abnormal production of white blood cells, which interferes with normal hematopoiesis (the manufacturing of healthy blood cells). Patients with leukaemia may present with symptoms such as anaemia, infections, bruising, bleeding and bone pain due to the lack of adequate normal blood cells as compared to cancerous ones.

ALL (Acute Lymphoblastic Leukaemia) represents the largest number of cases of leukaemia diagnosed in children. While most patients with ALL respond favourably to conventional treatments, many will eventually have their leukaemia relapse or show clinically significant signs of an insufficient response (i.e., treatment-resistant disease) to chemotherapy and/or radiation therapy.

What is CAR-T?

CAR-T therapy is an advanced immunotherapy that uses a patient's own T cells to fight cancer. The cells are collected, genetically modified to recognise specific proteins on leukaemia cells, multiplied in a laboratory, and reinfused into the body, where they identify and destroy cancer cells more effectively.

Why is CAR-T a breakthrough?

Traditional cancer treatments often are not specific to cancer cells and affect both healthy and cancer cells. This leads to diverse side effects from traditional cancer therapy.

CAR-T opens the way for a more specific approach to using the body's immune system to target only leukemic cells. Because CAR-T is a personalised approach to treatment, it has been successfully used to help children with relapsed or refractory leukaemia, where many patients have run out of possible conventional approaches. Many patients achieved remission with CAR-T treatment after unsuccessful conventional therapies.

CAR-T Therapy: Main Benefits for Children with Leukaemia

1. Targeted Treatment

One of the biggest benefits of CAR-T therapy is that it provides very specific destruction of leukaemia cells, while limiting damage to normal tissue. This targeted therapy improves treatment effectiveness and reduces many of the problems associated with traditional therapies.

2. Hope for Relapsed or Refractory Cases

Children whose leukaemia comes back or does not respond to traditional treatments usually have limited choices for treatment. CAR-T therapy has created a new and innovative treatment approach for these children that may provide the opportunity to achieve remission after a number of unsuccessful treatments.

3. Customized Treatment

Since CAR-T therapy is administered using a childâ€™s own immune cells, it is a highly individualised treatment option. This individualised model allows the CAR-T therapy to be specifically designed for each childâ€™s individual type of leukaemia.

4. Opportunity for Long-term Remission

CAR-T cells have been shown to persist in children for long periods of time, continuing to identify and kill leukaemia cells, thus continuing to provide immune surveillance and decreasing the chance of leukaemia returning.

5. Decreasing Need for Intensive Therapies

In some children, CAR-T therapy may eliminate the need for multiple rounds of chemotherapy or other intensive treatments.

The CAR-T Therapy Process

The treatment journey typically involves several carefully coordinated steps:

Step	Description
Patient Evaluation	Specialists assess whether the child is a suitable candidate for CAR-T therapy based on disease type, previous treatments, and overall health.
T-Cell Collection	T-cells are collected through leukapheresis, a procedure that separates and gathers immune cells from the patient's blood.
Cell Engineering	The collected T-cells are genetically modified in a specialised laboratory to express chimeric antigen receptors (CARs).
Cell Expansion	The engineered CAR-T cells are multiplied to produce millions of cancer-fighting cells.
Infusion	After a short course of preparatory chemotherapy, the modified CAR-T cells are infused back into the patient's bloodstream.
Monitoring and Recovery	Patients are closely monitored for treatment response and potential side effects, with ongoing specialised follow-up care during recovery

Challenges and Considerations

Though CAR-T therapy has had great success in treating childhood leukaemia, it does come with its challenges. Some side effects may occur if the immune system becomes overstimulated after a CAR T-cell infusion.

According to a study, "Cytokine Release Syndrome (CRS) occurs in 57%to 77% of patients. While severe (Grade â‰¥ 3) CRS was historically high in early trials, real-world registry data show that severe CRS rates have dropped to 16% to 21% due to optimised clinical management protocols."

Two of the most common side effects of a CAR-T Cell infusion are cytokine release syndrome (CRS), which can exhibit itself as a fever, fatigue, or other potentially serious side effects requiring hospitalisation or medical management, and neurological side effects, which, in some cases, may be experienced by some patients, thereby requiring careful monitoring during the treatment process.

Even if a child is a good candidate for CAR-T therapy, because of how highly specialized CAR-T therapy is, it generally requires a multi-disciplinary team and highly advanced medical facilities to be performed.

The Future of Treating Pediatric Leukaemia with CAR-T Therapy

The continued success of CAR-T therapy in treating children with leukaemia has prompted numerous researchers to extensively investigate expanding its use for treating children who have been diagnosed with other cancers. This will include continuing to develop ways to improve the efficacy of CAR-T therapy, while also working to reduce its side effects and to develop CAR-T therapies for other types of childhood cancers.

Additionally, researchers continue to explore the development of next-generation CAR-T technologies that can target multiple cancer markers and work to overcome resistance to CAR-T-based therapies. As the scientific community's understanding of CAR-T therapy evolves, the likelihood is that CAR-T therapy will play an increasingly significant role in treating children with cancer.

Conclusion

CAR-T therapy has been one of the biggest changes in treating childhood leukaemia in the last several decades, by targeting the child's immune system to help by giving them a new way of treating their cancer. This is also a personalised type of treatment that can potentially provide a child with a long-term remission.

Continuing advances in research and technology will allow CAR-T to improve the treatment of more children with leukaemias treated with this therapy and to provide more hope to families facing such a devastating diagnosis.

Reference:

Frequently Asked Questions

Eligibility depends on factors such as the type of leukaemia, previous treatments, overall health, and whether the disease has relapsed or become resistant to conventional therapies. A specialist evaluation is always required.

The complete CAR-T therapy process typically takes several weeks, including T-cell collection, laboratory engineering, cell expansion, infusion, and post-treatment monitoring.

Yes. Several advanced cancer centres in India offer CAR-T therapy for eligible pediatric leukaemia patients, supported by specialized oncology and cellular therapy teams.

Recovery timelines vary. Some children resume daily activities within weeks, while others require several months of follow-up care and immune system recovery.

Clinical studies have shown high remission rates in children with relapsed or refractory Acute Lymphoblastic Leukaemia (ALL), making CAR-T one of the most promising treatments in pediatric oncology.